Related Experiment Videos
Plasma beta-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation
Insights
Platelet activation markers, beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4), are elevated in atrial fibrillation (AF) patients, especially those with valvular heart disease (VHD). These findings suggest a link to thromboembolism and the need for antiplatelet therapy.
Area of Science:
- Cardiology
- Hematology
- Thrombosis Research
Background:
- Atrial fibrillation (AF) is a significant risk factor for thromboembolic events.
- Platelet activation plays a crucial role in thrombogenesis.
- Elevated levels of platelet-derived substances may indicate increased thrombotic risk in AF.
Purpose of the Study:
- To investigate the clinical significance of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) levels in patients with AF.
- To compare these levels in AF patients with and without valvular heart disease (VHD) against healthy controls.
- To explore the relationship between these markers and thromboembolic risk in AF.
Main Methods:
- Prospective study evaluating 26 AF patients with VHD, 73 AF patients without VHD, and 57 normal subjects.
- Measurement of serum beta-TG and PF-4 levels using established laboratory assays.
- Statistical analysis to compare marker levels between groups and assess correlations.
Main Results:
- Beta-TG levels were significantly higher in AF patients (with and without VHD) compared to normal subjects (p < 0.01).
- PF-4 levels tended to be higher in AF patients (with and without VHD) compared to controls.
- No significant correlation was found between beta-TG levels and age or heart rate in AF patients without VHD.
Conclusions:
- Increased levels of beta-TG and PF-4 suggest platelet activation in patients with AF, particularly those with VHD.
- These elevated markers may contribute to the high incidence of thromboembolism in AF patients.
- The findings highlight the potential necessity of antiplatelet therapy in managing AF patients at risk of thrombosis.
Abstract:
The clinical significance of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) levels were evaluated in 26 patients with atrial fibrillation (af) complicated by valvular heart disease (VHD), 73 patients with af but without valvular heart disease and 57 normal subjects. The beta-TG level was significantly higher in af patients without VHD than in normal subjects (49.4 +/- 35.8 ng/ml vs 31.2 +/- 14.0 ng/ml, p less than 0.01) and in af patients with VHD than in normals (64.1 +/- 52.8 ng/ml vs 31.2 +/- 14.0 ng/ml, p less than 0.01). Af patients with or without VHD tended to show high levels of PF4 compared with normals (af patients without VHD: 34.1 +/- 45.5 ng/ml, af patients with VHD: 18.6 +/- 27.2 ng/ml, normals: 11.6 +/- 8.2 ng/ml). There was no correlation between beta-TG levels and age in af patients without VHD or in normals. There was also no correlation between beta-TG levels and heart rate in af patients without VHD. The activation of platelets was suggested in patients with atrial fibrillation on the basis of increased levels of platelet releasing substances, especially in those with VHD. The high levels of beta-TG and PF4 in patients with atrial fibrillation may be one explanation for the high incidence of thromboembolism in these patients, indicating the necessity of antiplatelet therapy.